A phase I study of combination of panitumumab and bevacizumab in KRAS wild-type colorectal cancer patients who were previously treated with fluoropyrimidine, oxaliplatin, irinotecan, and bevacizumab.

被引：0

作者：

Takahashi, Naoki

Iwasa, Satoru

Tachikawa, Masanori

Fukahori, Masaru

Sudo, Kazuki

Sasaki, Yusuke

Shoji, Hirokazu

Honma, Yoshitaka

Okita, Natsuko

Takashima, Atsuo

Hamaguchi, Tetsuya

Boku, Narikazu

Shimada, Yasuhiro

Yamagiwa, Koki

Ebata, Yuka

Uchida, Yasuo

Honda, Kazufumi

Terasaki, Tetsuya

Yamada, Yasuhide

机构：

[1] Natl Canc Ctr, Gastrointestinal Med Oncol Div, 1-1 Tsukiji 5 chome, Tokyo, Japan

[2] Tohoku Univ, Grad Sch Pharmaceut Sci, Sendai, Miyagi 980, Japan

[3] Kurume Univ Hosp, Multidisciplinary Treatment Canc Ctr, Fukuoka, Japan

[4] Natl Canc Ctr, 1-1 Tsukiji 5 chome, Tokyo, Japan

[5] Natl Canc Ctr, Chuo Ku, 1-1 Tsukiji 5 chome, Tokyo, Japan

[6] Tohoku Univ, Grad Sch Pharmaceut Sci, Sendai, Miyagi 980, Japan

[7] Natl Canc Ctr, Res Inst, Tokyo 104, Japan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 04期

关键词：

D O I：

10.1200/jco.2016.34.4_suppl.759

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

759

引用

页数：1

共 50 条

[31] Panitumumab in the management of patients with KRAS wild-type metastatic colorectal cancer [J].

Hocking, Christopher M. ;

Price, Timothy J. .

THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2014, 7 (01) :20-37

[32] Multicenter phase II study of combination therapy with cetuximab and S-1 in patients with KRAS exon 2 wild-type unresectable colorectal cancer previously treated with irinotecan, oxaliplatin, and fluoropyrimidines (KSCC 0901 study) [J].

Takao Takahashi ;

Yasunori Emi ;

Eiji Oki ;

Kazuma Kobayashi ;

Akihito Tsuji ;

Mototsugu Shimokawa ;

Takaho Tanaka ;

Yoshito Akagi ;

Yutaka Ogata ;

Hideo Baba ;

Kazuhiro Yoshida ;

Shoji Natsugoe ;

Yoshihiko Maehara .

Cancer Chemotherapy and Pharmacology, 2016, 78 :585-593

[33] Multicenter phase II study of combination therapy with cetuximab and S-1 in patients with KRAS exon 2 wild-type unresectable colorectal cancer previously treated with irinotecan, oxaliplatin, and fluoropyrimidines (KSCC 0901 study) [J].

Takahashi, Takao ;

Emi, Yasunori ;

Oki, Eiji ;

Kobayashi, Kazuma ;

Tsuji, Akihito ;

Shimokawa, Mototsugu ;

Tanaka, Takaho ;

Akagi, Yoshito ;

Ogata, Yutaka ;

Baba, Hideo ;

Yoshida, Kazuhiro ;

Natsugoe, Shoji ;

Maehara, Yoshihiko .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (03) :585-593

[34] Bevacizumab with chemotherapy in patients with KRAS wild-type metastatic colorectal cancer: Czech registry data [J].

Kubackova, Katerina ;

Bortlicek, Zbynek ;

Pikus, Tomas ;

Linke, Zdenek ;

Pokorna, Petra ;

Vyzula, Rostislav ;

Prausova, Jana .

FUTURE ONCOLOGY, 2015, 11 (02) :225-232

[35] Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G [J].

Shitara, Kohei ;

Yonesaka, Kimio ;

Denda, Tadamichi ;

Yamazaki, Kentaro ;

Moriwaki, Toshikazu ;

Tsuda, Masahiro ;

Takano, Toshimi ;

Okuda, Hiroyuki ;

Nishina, Tomohiro ;

Sakai, Kazuko ;

Nishio, Kazuto ;

Tokunaga, Shoji ;

Yamanaka, Takeharu ;

Boku, Narikazu ;

Hyodo, Ichinosuke ;

Muro, Kei .

CANCER SCIENCE, 2016, 107 (12) :1843-1850

[36] Efficacy of panitumumab vs cetuximab in patients with wild-type KRAS exon 2 metastatic colorectal cancer treated with prior bevacizumab: Results from ASPECCT. [J].

Peeters, Marc ;

Kim, Tae Won ;

Li, Jin ;

Cascinu, Stefano ;

Ruff, Paul ;

Suresh, Attili Venkatasatya ;

Thomas, Anne ;

Tjulandin, Sergei ;

Guan, Xuesong ;

Price, Timothy Jay .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

[37] A 3-weekly schedule of irinotecan and panitumumab for wild-type KRAS metastatic colorectal cancer [J].

Hansen, Torben Frostrup ;

Andersen, Rikke Fredslund ;

Pallisgaard, Niels ;

Spindler, Karen-Lise Garm ;

Ploen, John ;

Keldsen, Nina ;

Lindebjerg, Jan ;

Sorensen, Flemming Brandt ;

Jakobsen, Anders .

COLORECTAL CANCER, 2014, 3 (02) :135-145

[38] Phase I study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancer [J].

Kemeny, N ;

Tong, W ;

Gonen, M ;

Stockman, J ;

Di Lauro, C ;

Teitcher, J ;

White, P ;

Price, C ;

Saltz, L ;

Sharma, S ;

Graham, MA .

ANNALS OF ONCOLOGY, 2002, 13 (09) :1490-1496

[39] Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer [J].

A F Hezel ;

M S Noel ;

J N Allen ;

T A Abrams ;

M Yurgelun ;

J E Faris ;

L Goyal ;

J W Clark ;

L S Blaszkowsky ;

J E Murphy ;

H Zheng ;

A A Khorana ;

G C Connolly ;

O Hyrien ;

A Baran ;

M Herr ;

K Ng ;

S Sheehan ;

D J Harris ;

E Regan ;

D R Borger ;

A J Iafrate ;

C Fuchs ;

D P Ryan ;

A X Zhu .

British Journal of Cancer, 2014, 111 :430-436

[40] Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer [J].

Hezel, A. F. ;

Noel, M. S. ;

Allen, J. N. ;

Abrams, T. A. ;

Yurgelun, M. ;

Faris, J. E. ;

Goyal, L. ;

Clark, J. W. ;

Blaszkowsky, L. S. ;

Murphy, J. E. ;

Zheng, H. ;

Khorana, A. A. ;

Connolly, G. C. ;

Hyrien, O. ;

Baran, A. ;

Herr, M. ;

Ng, K. ;

Sheehan, S. ;

Harris, D. J. ;

Regan, E. ;

Borger, D. R. ;

Iafrate, A. J. ;

Fuchs, C. ;

Ryan, D. P. ;

Zhu, A. X. .

BRITISH JOURNAL OF CANCER, 2014, 111 (03) :430-436

← 1 2 3 4 5 →